Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.00 Consensus PT from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $37.00.

A number of brokerages have weighed in on VRDN. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday, May 20th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. JMP Securities dropped their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Royal Bank Of Canada lowered their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new position in Viridian Therapeutics in the second quarter valued at approximately $170,000. Envestnet Asset Management Inc. acquired a new position in Viridian Therapeutics during the second quarter worth $187,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Viridian Therapeutics during the second quarter worth $180,000. TD Asset Management Inc increased its holdings in shares of Viridian Therapeutics by 174.8% in the second quarter. TD Asset Management Inc now owns 89,600 shares of the company’s stock valued at $1,253,000 after purchasing an additional 57,000 shares during the last quarter. Finally, J. Safra Sarasin Holding AG increased its holdings in shares of Viridian Therapeutics by 135.5% in the second quarter. J. Safra Sarasin Holding AG now owns 171,119 shares of the company’s stock valued at $2,392,000 after purchasing an additional 98,447 shares during the last quarter.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $17.41 on Friday. The company’s fifty day moving average is $15.63 and its 200-day moving average is $15.22. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -4.52 and a beta of 0.42. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. Viridian Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. Equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.